Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

Rang in Aktien #3368
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aktienkurs
$30.04
Marktkapitalisierung
$5.21B
Veränderung (1 Tag)
1.76%
Veränderung (1 Jahr)
83.28%
Land
US
Handel Cogent Biosciences, Inc. (COGT)

Kategorie

Healthcare
EPS für Cogent Biosciences, Inc. (COGT)
EPS zum June 2026 TTM: $-2.31
Laut den aktuellen Finanzberichten und dem Aktienkurs von Cogent Biosciences, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-2.31. Am Ende des Jahres 2023 betrug das EPS $-2.42 eine Steigerung gegenüber dem EPS von 2022, das $-2.26 betrug.
EPS-Verlauf von Cogent Biosciences, Inc. von 2015 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
2026 (TTM) $-2.31 -6.10%
2024 $-2.46 1.65%
2023 $-2.42 7.08%
2022 $-2.26 22.16%
2021 $-1.85 -69.17%
2020 $-6.00 51.13%
2019 $-3.97 -28.47%
2018 $-5.55 60.87%
2017 $-3.45 11.29%
2016 $-3.10 174.34%
2015 $-1.13 0.00%
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -849.78%
US
$-7.98 245.45%
US
$-5.29 129.00%
AU
- -
CH
$27.74 -1,300.87%
NL